The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...

New studies raise the possibility that GLP-1 medications beat aspirin in reducing colorectal cancer risk, and may improve outcomes for people who do develop the disease.

Christian Reconstructionism, a little-known movement to rebuild society on biblical law, can often shape US debates over ...

CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testingMORRISVILLE, ...

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultrasensitive and early molecular residual disease (MRD) detection, today announced the ...

Background mucosal inflammation at CRC diagnosis is linked to worse recurrence-free and cancer-specific survival in ulcerative colitis.

CITCCA study data demonstrate strong association between ctDNA status and recurrence risk in stage I-III colorectal cancerMORRISVILLE, N.C.--(BUSINESS WIRE)--#ASCOGI--SAGA Diagnostics, a pioneer in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

The New Patriotic Party (NPP), has constituted a joint committee to study the final proposals submitted by the Constitution Review Committee (CRC) to President John Dramani Mahama and advise the party ...

LONG BEACH, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) (“CRC”) today closed its all-stock combination with Berry ...

Welcome to Natera's 2025 Third Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, November 6, 2025. I'd now like to turn ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...